Free Trial
→ BUY THIS: Claim a backdoor stake in SpaceX before June 12 (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:IMRX

Immuneering Q1 2026 Earnings Report

Immuneering logo
$4.27 -0.21 (-4.69%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$4.26 -0.01 (-0.23%)
As of 06/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immuneering EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Immuneering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immuneering Announcement Details

Quarter
Q1 2026
Date
5/15/2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
7:30AM ET

Upcoming Earnings

Immuneering's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Immuneering's Q1 2026 Press ReleasePress Release
(8-K)
Immuneering's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Immuneering Earnings Headlines

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
June 6 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30822025
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
June 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/imrx-stock-track-worst-day-195801680.html
BUY THIS: Claim a backdoor stake in SpaceX before June 12
SpaceX isn't public yet, but one trade available in a standard brokerage account could give you pre-IPO exposure before the window closes June 12. Analysts have pointed to a potential $122 billion windfall on IPO day - a figure larger than the market cap of most publicly traded companies. This play positions you ahead of the broader public market.tc pixel
June 6 at 1:00 AM  |  Chaikin Analytics (Ad)
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript
June 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4910624-immuneering-corporation-imrx-discusses-positive-atebimetinib-asco-data-update-in-first-line
Immuneering Corporation Reports Promising 17.3 Months Median Overall Survival in First-Line Pancreatic Cancer Trial with Atebimetinib
June 1, 2026  |  quiverquant.comQ
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304230/0/en/immuneering-presents-compelling-17-3-month-median-overall-survival-and-favorable-tolerability-with-atebimetinib-chemotherapy-in-first-line-pancreatic-cancer-patients-at-asco.html
See More Immuneering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email.

About Immuneering

Immuneering (NASDAQ:IMRX) (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy. Immuneering also maintains discovery- and preclinical-stage programs targeting inflammatory and immuno-oncology indications. Through strategic collaborations and licensing partnerships, the company extends the application of its computational platform across multiple therapeutic areas and works alongside pharmaceutical partners to co-develop novel treatments.

Founded in 2016, Immuneering is headquartered in Cambridge, Massachusetts, and operates research facilities in the United States. After completing its initial public offering on the Nasdaq in early 2021, the company has continued to expand its computational infrastructure, diversify its pipeline through in-house research and external collaborations, and advance its mission to bring more effective, AI-driven therapies to patients worldwide.

View Immuneering Profile
Earnings Tools